UCB S.A.: Seizures trials

The registry lists 77 Seizures studies with UCB S.A. as lead sponsor. 1 are open to participants now and 60 have results posted.

Phase 2 20Phase 3 51Phase 4 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))RecruitingNCT05135091Phase 3
• A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant EpilepsyTerminatedNCT03739840Phase 3Results posted
• Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure PatternCompletedNCT03478982Phase 2Results posted
• Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant EpilepsyCompletedNCT03373383Phase 2Results posted
• Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant EpilepsyTerminatedNCT03370120Phase 2Results posted
• A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of AgeCompletedNCT03340064Phase 3Results posted
• A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic SeizuresTerminatedNCT03325439Phase 3Results posted
• A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet SyndromeTerminatedNCT03299842Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit SettingCompletedNCT03021018Phase 2Results posted
• An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet SyndromeCompletedNCT02823145Phase 3Results posted
• Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset SeizuresCompletedNCT02687711Results posted
• A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet SyndromeCompletedNCT02682927Phase 3Results posted
• Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset SeizuresCompletedNCT02477839Phase 3Results posted
• Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic SeizuresCompletedNCT02408549Phase 3Results posted
• A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic MedicationsCompletedNCT02408523Phase 3Results posted
• Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset SeizuresCompletedNCT02192814Phase 3Results posted
• A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure ClustersTerminatedNCT02161185Phase 3Results posted
• A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset SeizuresCompletedNCT02124564Phase 3Results posted
• Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic SeizuresTerminatedNCT02088957Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.CompletedNCT01969851Phase 2Results posted
• A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset SeizuresCompletedNCT01964560Phase 3Results posted
• Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset SeizuresCompletedNCT01954121Phase 3Results posted
• Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset SeizuresCompletedNCT01921205Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset SeizuresCompletedNCT01832038Phase 3Results posted
• A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset SeizuresCompletedNCT01710657Phase 3Results posted
• Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination TherapyCompletedNCT01673282Results posted
• Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure ClustersTerminatedNCT01529034Phase 3Results posted
• An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal EpilepsyCompletedNCT01506882Phase 3Results posted
• An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset SeizuresCompletedNCT01407523Phase 2Results posted
• An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic SeizuresCompletedNCT01398956Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure ClustersTerminatedNCT01390220Phase 3Results posted
• A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic SeizuresCompletedNCT01292837Phase 3Results posted
• Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset SeizuresCompletedNCT01261325Phase 3Results posted
• Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and OlderCompletedNCT01236001Results posted
• Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset SeizuresCompletedNCT01229735Phase 4Results posted
• A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)CompletedNCT01228747Phase 3Results posted
• Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118962Phase 2Results posted
• Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118949Phase 2Results posted
• An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial SeizuresCompletedNCT01063764Phase 3Results posted
• Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset SeizuresCompletedNCT00955357Phase 4Results posted
• A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial SeizuresCompletedNCT00938431Phase 2Results posted
• Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset SeizuresCompletedNCT00771927Results posted
• A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset SeizuresTerminatedNCT00699283Phase 3Results posted
• A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset SeizuresTerminatedNCT00698581Phase 3Results posted
• Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset SeizuresCompletedNCT00655551Phase 3Results posted
• Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset SeizuresCompletedNCT00655486Phase 3Results posted
• To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial SeizuresCompletedNCT00552305Phase 2Results posted
• Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset SeizuresCompletedNCT00530855Phase 3Results posted
• Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial SeizuresCompletedNCT00522275Phase 3Results posted
• Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset SeizuresCompletedNCT00520741Phase 3Results posted
• Assess Safety and Efficacy of Lacosamide in Patients With Partial SeizuresCompletedNCT00515619Phase 3Results posted
• Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresCompletedNCT00490035Phase 3Results posted
• Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresCompletedNCT00464269Phase 3Results posted
• Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial SeizuresCompletedNCT00419393Phase 3Results posted
• Conversion to Monotherapy Study With Keppra XR for Partial SeizuresCompletedNCT00419094Phase 3Results posted
• A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset SeizuresCompletedNCT00367432Phase 3Results posted
• A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.CompletedNCT00175825Phase 2Results posted
• Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label MethodCompletedNCT00160615Phase 3Results posted
• Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset SeizuresCompletedNCT00152516Phase 3Results posted
• Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking LevetiracetamCompletedNCT00152503Phase 2Results posted
• Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset SeizuresCompletedNCT00152451Phase 2Results posted
• A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Active, not recruitingNCT05064878Phase 3
• A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationCompletedNCT03685630Phase 3
• Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic SeizuresNo longer availableNCT03559673
• Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset SeizuresCompletedNCT00615615Phase 3
• Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset SeizuresCompletedNCT00610454Phase 2
• A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence SeizuresCompletedNCT00545012Phase 2
• A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset SeizuresWithdrawnNCT00422110Phase 2/3
• UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)CompletedNCT00345475
• A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset SeizuresCompletedNCT00280696Phase 3
• A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary GeneralizationCompletedNCT00220415Phase 3
• A Study of Brivaracetam in Subjects With Partial Onset SeizuresCompletedNCT00175929Phase 2
• A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.CompletedNCT00175890Phase 3
• Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic SeizuresCompletedNCT00160550Phase 3
• Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial SeizuresCompletedNCT00151879Phase 2/3
• SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary GeneralizationCompletedNCT00136019Phase 3
• A 19-week Cognition Study of Levetiracetam in Children With Partial Onset SeizuresCompletedNCT00105040Phase 2